ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ TUYẾN VÚ THỂ NỘI ỐNG TẠI BỆNH VIỆN UNG BƯỚU HÀ NỘI

Abstract

Objective: To describe the clinical, paraclinical characteristics and evaluate the treatment outcomes of ductal carcinoma in situ (DCIS) at Hanoi Oncology Hospital. Patients and methods: A cross-sectional study was conducted on 70 patients diagnosed and treated for DCIS at Hanoi Oncology Hospital between June 2022 and October 2024. Data were collected from medical records and patient interviews, and analyzed using SPSS 20.0. Results: The mean age was 53.4 ± 11.4 years, with the 41–50 age group accounting for 34.3%. Most patients (84.3%) presented with palpable masses. Lesions were predominantly in the left breast (51.4%) and upper outer quadrant (57.1%). Tumor size ranged mostly from 11–25 mm (48.6%). Clinically malignant diagnosis was present in 75.7%. On mammography, 60.9% were BIRADS 4; ultrasound showed typical spiculated hypoechoic masses in 51.4%. Core needle biopsy confirmed DCIS in 69.0%. Histologically, the comedo subtype was most common (57.1%), with grade III tumors accounting for 71.4%. Immunohistochemistry revealed ER(+) in 57.1%, PR(+) in 45.7%, and Her2/neu(+) in 60%. Mastectomy was performed in 61.4%, with an average surgical time of 53.2 minutes. Postoperative complications were rare (2.8%). Adjuvant radiotherapy was given to 1.4%, and hormonal therapy to 42.9%. No recurrence or metastasis was observed during follow-up. Conclusion: DCIS has an excellent prognosis with early detection and appropriate treatment. Histopathology and immunohistochemistry are crucial in treatment planning. Appropriate surgery combined with individualized hormonal management and close follow-up contributes to optimal disease control.